Daily General Analysis
May 13, 2026
Hey everyone! Today's coffee is hot, the S&P is catching its breath, and the news doesn't stop. Let's get straight to what affects your wallet.
### #1 – US Inflation Surges, Triggering Red Alert
Summary: The US Producer Price Index (PPI) rose 6% over the last year, driven by fuel costs, and the bill has already reached the end consumer.
Verdict: I would reduce exposure to short-term equities. The Fed will have to keep interest rates high for longer, squeezing corporate margins.
Assets/Sectors: VIX (volatility), short-term Treasuries (SHY), consumer discretionary sector (XLY), and energy (XLE).
### #2 – Nvidia Swallows Oracle in 4 Days: +$591 Billion in Valuation
Summary: Nvidia (NVDA) added over half a trillion dollars in market value in just four trading sessions, surpassing Oracle's total value on its own.
Verdict: I would Hold (with a tight grip). The stock is overbought, but the flow of AI news remains favorable. I wouldn't sell now, but I also wouldn't buy at the peak.
Assets/Sectors: NVDA, AMD, semiconductor sector (SMH), and cloud providers (AMZN, MSFT).
### #3 – JPMorgan Launches Second Fund on Ethereum: Wall Street Goes All-In on Tokenization
Summary: JPMorgan (JPM) filed its second tokenized fund on Ethereum, signaling that blockchain adoption by major banks has moved beyond the theoretical stage.
Verdict: I would Buy exposure to blockchain infrastructure. The move by big banks legitimizes the market and drives demand for institutional digital assets.
Assets/Sectors: ETH, JPM, crypto custody sector (COIN), and tokenization platforms.
### #4 – BMS Pays $15.2 Billion in Deal with Chinese Pharmaceutical Company
Summary: Bristol Myers Squibb (BMY) closed a mega-deal worth $15.2 billion with China's Jiangsu Hengrui to access 13 new drug programs, attempting to escape the "patent cliff."
Verdict: I would Buy BMY. The move is defensive and smart: instead of losing revenue from expiring patents, it buys a fresh pipeline at a high but necessary cost. The market is pricing in too much risk for this stock.
Assets/Sectors: BMY, XBI (biotechnology), IBB (pharma), and the Chinese healthcare sector.
### #5 – EU Ban Could Cost Brazilian Agribusiness $2 Billion
Summary: The EU is considering banning Brazilian meat imports amid environmental pressures, which could strip nearly $2 billion from the national agribusiness sector.
Verdict: I would reduce exposure to meatpackers heavily dependent on the European market.
Assets/Sectors: JBSS3, MRFG3, animal protein sector (BRFS3), and ethanol (CSAN3) – which could suffer collateral image damage.
### #6 – Trump-Xi: Super Meeting Defines the Future of the Global Economy
Summary: The upcoming meeting between Donald Trump and Xi Jinping promises to redefine the tone of the US-China trade relationship for years to come, with Taiwan as a backdrop.
Verdict: I would Hold positions in assets tied to Asia, but with caution. Any announcement of tariffs or restrictions could generate immediate volatility.
Assets/Sectors: FXI (China large cap), TSM, global logistics sector, and the Japanese yen (JPY).
---
### Immediate Opportunities
- Banking Blockchain: JPMorgan's move and fund tokenization pave the way for crypto infrastructure companies like COIN and even ETH.
- Pharma Bargain: BMY is being penalized by a market that didn't understand the deal. It could be a opportunistic buy for those with a strong stomach.
- Short-Term Volatility: With PPI rising, put options on the VIX could pay off quickly if the market decides to correct.
### Risks on the Radar
- Resilient Inflation: If the May CPI comes in hot, the Fed might have to raise rates again. This would sink growth stocks and crypto.
- Geopolitical Risk – Taiwan: Any tougher move by China or the US regarding the island could trigger a broad sell-off.
- European Meat Ban: If confirmed, it could contaminate other Brazilian agribusiness sectors, like soy and coffee, by reputation.
---
[Source: CBS News – Inflation]
[Source: Crypto Briefing – Nvidia]
[Source: TNW – JPMorgan]
[Source: TNW – BMS]
[Source: Metrópoles – EU Ban]
[Source: Adevărul – Trump-Xi]
_This analysis is personal opinion and does not constitute investment advice._
